Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B003 alone or BL-B01D1 + SI-B003 in advanced or metastatic NSCLC, nasopharyngeal carcinoma, and other solid tumors
CTR20232093Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SI-B003, izalontamab brengitecan in non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma (NPC), Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Feb 2024; status: active.
02
Drugs
SI-B003izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)nasopharyngeal carcinoma (NPC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232093.